Interestingly, expression of the newly identified ligand FGL1 has also been shown to be upregulated in cancer, and blockade of the FGL1-LAG-3 interaction stimulates immune responses and exhibits therapeutic effects on mouse tumor models (MC38 colon cancer and Hepa1-6 liver cancer) (87). The gene discussed is FGL1; the disease is colonic neoplasm.